High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
Mark W. Brunvand(University of Washington), CD Buckner(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ted Gooley(Fred Hutch Cancer Center), Taner Demirer(Fred Hutch Cancer Center), Thomas R. Chauncey(City Of Hope National Medical Center), E. Soll(University of Washington), Scott D. Rowley(Johns Hopkins Hospital), N. Zuckerman(Oregon Health & Science University), Jack W. Singer(NorthShore University HealthSystem), Richard T. Maziarz(Oregon Health & Science University), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), K Lilleby(University of Washington), Jean E. Sanders(Carolinas Medical Center), Peter A. McSweeney(Mesoblast (United States)), Charles H. Weaver(University of Washington), P L Weiden, K Schiffman(University of Washington), R. A. Clift(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Paul G. Montgomery(St. Luke's Mountain States Tumor Institute), Ronald V. Dorn(St. Luke's Mountain States Tumor Institute), A Fefer(University of Washington), F R Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Leona Holmberg, Patrick Martin(University of Washington), Oliver W. Press(Fred Hutch Cancer Center)
PubMed
July 1, 1996
Cited by 645
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k